Overview

• Scientists published a new delete-to-recruit strategy that uses CRISPR-Cas9 to remove DNA segments and bring enhancers closer to target genes.
• The approach has successfully reactivated fetal globin in laboratory and human blood stem cells from healthy donors and patients with sickle cell disease.
• By reviving dormant embryonic genes instead of inserting new genetic material, the method could provide a streamlined alternative for sickle cell and beta-thalassemia therapies.
• Researchers highlight that the delete-to-recruit technique may reduce off-target risks and lower costs compared with Europe’s existing 2024-approved gene therapies.
• Investigators suggest the enhanced control of gene-enhancer interactions could be applied to other genetic diseases where reactivating backup genes offers compensatory benefits.